Team
Meet Our Leadership
Douglas Boothe, Chief Executive Officer
Mr. Boothe is a dynamic pharmaceutical leader with extensive accomplishments in the specialty, generic, and over-the-counter pharmaceutical markets. Prior to joining Edenbridge, now Dexcel Pharma USA, Doug was President and CEO of Akorn Pharmaceuticals. Doug was previously the President, Generic Business for Impax Laboratories up to the company’s acquisition by Amneal Pharmaceuticals. Prior pharmaceutical leadership roles include Executive Vice President and Generic Manager of Perrigo Company’s Specialty and Generic Pharmaceutical business, CEO of Actavis Inc., Vice President/General Manager at Alpharma, and Vice President, Emerging Technologies at Pharmacia Inc. Doug holds an MBA from the Wharton School of Business and a BSE in Mechanical and Aerospace Engineering from Princeton University. Doug has served on the Board of Directors for Euclid Systems (a specialty contact lens manufacturer) and on the Executive Board for the Generic Pharmaceutical Association (GPhA n/k/a Association for Accessible Medicines).
Marc Padre, Chief Finance Officer
Mr. Padre has held finance positions in large multi-national publicly traded companies as well as small privately held pharmaceutical companies. Prior to joining Edenbridge, now Dexcel Pharma USA, Mr. Padre served as Vice President, Corporate Controller for Vertice Pharmaceuticals and prior to that Mr. Padre served as the US Controller for Bausch Health Companies during a period of seventeen stock acquisitions and growth in market capital from $2B to $80B. Mr. Padre also served as an adjunct professor in accounting and information systems at The College of New Jersey. Mr. Padre earned Summa Cum Laude honors while earning a B.S. degree in Accounting from Arizona State University and was formerly licensed as a CPA in California.
Itamar Ben-Anat, SVP, Chief Operating Officer
As Dexcel Pharma USA COO, Mr. Ben-Anat oversees the company’s operational resources including external manufacturing and supply, Quality, R&D, and Regulatory Affairs. Prior to joining Edenbridge, now Dexcel Pharma USA, Itamar was the AVP of Strategic Operations and Project Management for Lannett Company, where he was responsible for the end-to-end delivery of the company’s new product development and new product launch programs, as well as for Portfolio Governance and Alliance Management. Previously, Itamar spent 15 years with Teva Pharmaceuticals where he held positions of increasing responsibility in the areas of Specialty R&D, Global Operations, and Commercial. Itamar holds a B.Sc. in Industrial Engineering and Management and a B.Sc. in Civil Engineering both from the Technion – Israel institute of Technology, as well as an MBA from Bar-Ilan University, Israel.
Daniel G. Worley Jr., PharmD, Esq., Senior Vice President, Business Development & General Counsel
Dr. Worley is a patent attorney and registered pharmacist who is responsible for all business development and legal operations at Dexcel Pharma USA. Prior to joining Edenbridge, now Dexcel Pharma USA, Dr. Worley was an associate at Haug Partners LLP (f/k/a Frommer Lawrence & Haug LLP) where he specialized in patent and FDA regulatory law. Dr. Worley holds a PharmD, magna cum laude, from Rutgers University and a JD, cum laude, from Seton Hall University.
Mike White, Senior Vice President, Sales & Marketing
Mr. White is responsible for the development and execution of Dexcel Pharma USA’s generic sales & marketing strategy and leading all trade relations, product launches, sales infrastructure, customer service, and sales logistics related to Edenbridge’s generic product portfolio. Prior to joining Edenbridge, now Dexcel Pharma USA, Mr. White held various sales & marketing roles at Nostrum Laboratories, Actavis, Rising Pharmaceuticals, and PACK Pharmaceuticals. Mr. White holds a B.A. in Political Science from Purdue University.
Debashis Das, Ph.D., Vice President, R&D
Dr. Das is responsible for all product development & technical transfer activities at Dexcel Pharma USA. Prior to joining Edenbridge, now Dexcel Pharma USA, Dr. Das held senior roles at Endo and Par Pharmaceuticals. Dr. Das possesses over 20 years of experience in providing analytical support to development of IND, NDA, and ANDA drug products. Dr. Das obtained his Ph.D. degree in Chemistry from Northern Illinois University.
Jason Nowack, Vice President, Quality Assurance
Mr. Nowack is responsible for all internal quality systems, oversight of external quality activities and DSCSA compliance for Dexcel Pharma USA. Mr. Nowack has over 21 years of experience in the pharmaceutical industry with 15 years in quality assurance. Prior to joining Edenbridge, now Dexcel Pharma USA, Mr. Nowack was most recently the site quality head for Aprecia Pharmaceuticals. Mr. Nowack holds a B.S. degree in biotechnology from Rutgers University.
Scott Barry, Vice President, Finance
Mr. Barry brings to Dexcel Pharma USA twenty years of financial experience, with many of those years spent within the pharmaceutical industry. Most recently, Mr. Barry served as Senior Finance Director for Bausch & Lomb and during his twelve years with Bausch & Lomb Mr. Barry held roles with increasing responsibilities and a focus on FP&A, driving performance, and increasing profitability. Throughout his career, Mr. Barry has worked across multiple industries, including pharmaceuticals, consumer products, manufacturing, and healthcare services. Mr. Barry holds a B.S. degree in Finance from Bryant University and an MBA in Strategic Business and Management from Rutgers University.
Stephanie Jomisko, Senior Director, Marketing
Ms. Jomisko is responsible for marketing activities, including generic product pricing, launch strategies and planning, while reinforcing trade relations by overseeing sales operations and customer service. Ms. Jomisko is an accomplished leader that has held commercial operations and marketing positions throughout her career in multinational publicly traded companies as well as smaller, privately held life science companies both with pharmaceutical manufacturers and wholesalers. Prior to joining Edenbridge, now Dexcel Pharma USA, she held leadership positions at Dr. Reddy’s Laboratories, North America, as Director of Pricing and Director of Commercial Contracts. Prior to that, Ms. Jomisko has held diverse roles of increasing responsibility at Hi-Tech Pharmaceuticals, Cardinal Heath and Bellco Drug. Ms. Jomisko holds a B.S. degree in Biology from Roanoke College.
Shruthi Surendra, Manager, Regulatory Affairs
Ms. Surendra oversees all aspects of regulatory strategy and compliance at Dexcel Pharma USA, ensuring that products meet stringent industry standards and regulatory requirements. Before joining Edenbridge, now Dexcel Pharma USA, she held key positions in regulatory affairs at Lupin Pharmaceuticals and Rising Pharmaceuticals, where she successfully managed regulatory submissions for multiple new products and led initiatives to enhance compliance protocols. Additionally, she contributed to Quality Assurance at Biocon Ltd, bringing over a decade of experience in the field. Ms. Surendra holds an M.S. in Epidemiology from SUNY Buffalo, an MBA in Healthcare Management, and a Master’s in Microbiology. Her expertise in and dedication to regulatory excellence play a crucial role in the Company’s commitment to bringing safe and effective therapies to market.
